Evidence map›Paper›PMID 32643093›Full record

ArticleMetabolic brain disease2020

The role of lipid peroxidation in individuals with autism spectrum disorders.

Kunio Yui, George Imataka, Hitomi Sasaki, Ryoichi Shiroki

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Consequences of Disturbing Manganese Homeostasis.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kunio YuiDepartment of Urology, Fujita Medical University School of Medicine, Aichi, 470-1192, Japan. yui16@bell.ocn.ne.jp.ORCID http://orcid.org/0000-0002-3714-2956
George ImatakaDepartment of Pediatrics, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Hitomi SasakiDepartment of Urology, Fujita Medical University School of Medicine, Aichi, 470-1192, Japan.
Ryoichi ShirokiDepartment of Urology, Fujita Medical University School of Medicine, Aichi, 470-1192, Japan.
Fujita Health University · JPDokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of malondialdehyde-modified low-density lipoprotein (MDA-LDL), an oxidized LDL, in the pathophysiology of autism spectrum disorder (ASD) is unclear. We studied association between MDA-LDL and behavioral symptoms in 11 individuals with ASD and 7 age -matched normal controls. Behavioral symptoms were assessed using the Aberrant Behavior Checklists (ABC). Because small sample size in this study, three measures were conducted: first, employment of adaptive Lasso for enhancing the accuracy of prediction and interpretability; second, calculation of coefficient of variation for an appropriate selection of plasma variables; and third, selection of good candidates of plasma variables. Plasma levels of MDA-LDL, eicosapentaenoic acid, docosahexaenoic acid (DHA) and DHA/arachidonic acid ratios were significantly higher, while plasma superoxide dismutase (SOD) levels were significantly lower in the ASD group than in the control group. The total ABC scores were significantly higher in the ASD group than in the control group. Multiple linear regression analysis and the adaptive Lasso revealed association of increased plasma DHA levels with the ABC total scores and increased plasma MDA-LDL levels. Such association between DHA and plasma MDA-LDL levels may contribute to behavior in individuals with ASD.

Indexed as

AdolescentArachidonic AcidAutism Spectrum DisorderChildChild, PreschoolDocosahexaenoic AcidsEicosapentaenoic AcidFemaleHumansLipid PeroxidationLipoproteins, LDLMaleMalondialdehydeYoung AdultArachidonic AcidDocosahexaenoic AcidsEicosapentaenoic AcidLipoproteins, LDLMalondialdehydeAutistic behaviorDocosahexaenoic acid (DHA)Lipid peroxidationMalondialdehyde-modified low-density lipoprotein

Identifiers

PMID32643093
OpenAlexW3042092763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.